levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...7677787980818283848586...9091»
  • ||||||||||  levofloxacin / Generic mfg.
    PK/PD data, Journal:  Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. (Pubmed Central) -  Mar 2, 2021   
    According to the pharmacokinetic/pharmacodynamic surrogate index (AUC/MIC) the levofloxacin dose regimen (after oral administration) used in the present study could be active against bacteria at a minimum inhibitory concentration (MIC) <0.24 μg/ml in geese. In addition, drug accumulation in the liver might be controlled using an estimated preliminary withdrawal time of 90 h.
  • ||||||||||  levofloxacin / Generic mfg.
    Clinical, Journal:  Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. (Pubmed Central) -  Feb 26, 2021   
    Nevertheless, the selectivity index values of the conjugates, both for the bacteria and human pathogenic yeasts, remained favourable. Step-down oral levofloxacin for children with FN who are afebrile with an ANC ≤ 500 at discharge is feasible and resulted in similar clinical outcomes compared to home IV antibiotics.
  • ||||||||||  clarithromycin / Generic mfg.
    Clinical, Journal:  Epidemiological investigation and antimicrobial susceptibility analysis of mycoplasma in patients with genital manifestations. (Pubmed Central) -  Feb 25, 2021   
    Step-down oral levofloxacin for children with FN who are afebrile with an ANC ≤ 500 at discharge is feasible and resulted in similar clinical outcomes compared to home IV antibiotics. Our findings indicate a high burden of mycoplasmas infection and antimicrobial resistance of mycoplasmas infection among females, and josamycin and minocycline may be recommended as the primary choice in clinical treatment of anti-mycoplasmas.
  • ||||||||||  levofloxacin / Generic mfg.
    Trial completion date, Trial primary completion date:  Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer (clinicaltrials.gov) -  Feb 25, 2021   
    P4,  N=144, Recruiting, 
    Our findings indicate a high burden of mycoplasmas infection and antimicrobial resistance of mycoplasmas infection among females, and josamycin and minocycline may be recommended as the primary choice in clinical treatment of anti-mycoplasmas. Trial completion date: Apr 2021 --> Dec 2022 | Trial primary completion date: Oct 2020 --> Sep 2022
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Benefits of Polydopamine as Particle/Matrix Interface in Polylactide/PD-BaSO Scaffolds. (Pubmed Central) -  Feb 23, 2021   
    Polydopamine functionalized barium sulfate particles also facilitated the adsorption and release of the antibiotic levofloxacin. Analysis of the antibacterial capacity of these composites and the metabolic activity and proliferation of human dermal fibroblasts in vitro demonstrated that these materials are non-cytotoxic and can be 3D printed to formulate complex biocompatible materials for bone fixation devices.
  • ||||||||||  Lamprene (clofazimine) / Novartis
    Journal:  TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice. (Pubmed Central) -  Feb 20, 2021   
    Adding T to ALEZC might shorten the MDR-TB treatment duration from ≥ 9 months to ≤ 5months, as five months of treatment with ALEZCT achieved zero relapse rates in 2 animal experiments. These findings indicate that T exhibits a highly synergistic sterilizing activity when combined with C. All isolates from relapsing mice remained sensitive to each drug, suggesting that the relapse was not due to drug resistance but rather associated with the type of regimen.
  • ||||||||||  piperacillin sodium/tazobactam sodium / Generic mfg., levofloxacin / Generic mfg.
    Clinical, Journal:  Chromobacterium violaceum infection on lower limb skin: A case report. (Pubmed Central) -  Feb 20, 2021   
    When an infection is suspected, samples should be immediately sent for microbial culture. Timely treatment on the basis of drug sensitivity test results can prevent further complications.
  • ||||||||||  Cubicin (daptomycin) / Merck (MSD)
    Observational data, Retrospective data, Journal:  Uropathogens antibiotic susceptibility as an indicator for the empirical therapy used for urinary tract infections: a retrospective observational study. (Pubmed Central) -  Feb 20, 2021   
    Nitrofurantoin, tigecycline, daptomycin, teicoplanin, vancomycin and linezolid had a high effect against Gram-positive isolates. The leading causative isolates especially the most predominant Gram-negative isolates E. coli and K. pneumoniae show high resistance rates against important antibiotics including penicillin/β-lactamase inhibitors piperacillin/tazobactam, ceftazidime cefepime, ciprofloxacin, levofloxacin and trimethoprim/sulfamethoxazole which call for reconsidering them for treatment of UTI.
  • ||||||||||  amitriptyline / Generic mfg.
    Journal:  β-cyclodextrin Polymerized in Cross-Flowing Channels of Biomass Sawdust for Rapid and Highly Efficient Pharmaceutical Pollutants Removal from Water. (Pubmed Central) -  Feb 17, 2021   
    Consequently, the β-CD/WS filter device shows a high removal efficiency of over 97.5% within 90 seconds for various pharmaceutical contaminants including propranolol, amitriptyline, chlortetracycline, diclofenac and levofloxacin, and a high saturation uptake capacity of 170, 156, 257, 159, and 185 mg g-1, respectively. The high-performance wood-sawdust-based cross-flow filtration opens new avenues for solving the global water pollution issues, especially those caused by pharmaceutical contaminants.
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    Journal:  Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. (Pubmed Central) -  Feb 16, 2021   
    Conclusion This repertoire portrays the emergence of MRSA in laboratory workers which clearly indicates the necessity of complying with the sanitary and antibacterial guidelines and adhering to the rational use of antibiotics to prevent nosocomial infections. Our data documented a decreasing trend for rifabutin-based therapy efficacy according to previous therapy failures, whilst this did not occur for Pylera®.
  • ||||||||||  levofloxacin / Generic mfg.
    Enrollment open, Surgery:  Levofloxacin Ocular Implant for Ocular Surgery (clinicaltrials.gov) -  Feb 16, 2021   
    P1,  N=5, Recruiting, 
    Our data documented a decreasing trend for rifabutin-based therapy efficacy according to previous therapy failures, whilst this did not occur for Pylera®. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  InDEX: The Individualized M(X) Drug-resistant TB Treatment Strategy Study (clinicaltrials.gov) -  Feb 5, 2021   
    P4,  N=448, Recruiting, 
    Recruiting --> Completed | Trial completion date: Sep 2020 --> Jan 2021 Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  prednisone / Generic mfg., levofloxacin / Generic mfg.
    [VIRTUAL] Acute Sensorineural Hearing Loss - an Unusual Presentation of Uncontrolled DM (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1134;    
    Clinical case: A 34-year-old male with type 2 diabetes mellitus (A1c 6.5% -diagnosed 6 months prior), hypertension, hyperlipidemia, and morbid obesity presented with shortness of breath and acute hearing loss without tinnitus, after being treated for pneumonia and otitis media with a course of levofloxacin for 7 days...The patient received one dose of empiric prednisone...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  TBM-KIDS: Optimizing Treatment to Improve TBM Outcomes in Children (clinicaltrials.gov) -  Jan 25, 2021   
    P1/2,  N=38, Completed, 
    The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021. Active, not recruiting --> Completed | N=120 --> 38 | Trial completion date: Jun 2021 --> Nov 2020 | Trial primary completion date: Jun 2021 --> Nov 2020
  • ||||||||||  levofloxacin / Generic mfg.
    Enrollment open, Trial initiation date:  Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (clinicaltrials.gov) -  Jan 18, 2021   
    P4,  N=360, Recruiting, 
    Active, not recruiting --> Completed | N=120 --> 38 | Trial completion date: Jun 2021 --> Nov 2020 | Trial primary completion date: Jun 2021 --> Nov 2020 Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020
  • ||||||||||  Trial completion date, Trial primary completion date:  Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) -  Jan 8, 2021   
    P1/2,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Apr 2022 Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg.
    Trial completion date, Trial primary completion date:  TBM-KIDS: Optimizing Treatment to Improve TBM Outcomes in Children (clinicaltrials.gov) -  Nov 13, 2020   
    P1/2,  N=120, Active, not recruiting, 
    Phase classification: P3 --> P2 | Trial completion date: Jan 2024 --> Jul 2025 | Trial primary completion date: Jan 2024 --> Jul 2025 Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
  • ||||||||||  levofloxacin / Generic mfg., doxycycline / Generic mfg.
    New P4 trial:  LOAD VS Levofloxacine Concomitant (clinicaltrials.gov) -  Nov 11, 2020   
    P4,  N=80, Recruiting, 
  • ||||||||||  Trial primary completion date:  APPACIII: Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis (clinicaltrials.gov) -  Nov 10, 2020   
    P=N/A,  N=147, Enrolling by invitation, 
    Recruiting --> Completed | Phase classification: P2 --> P3 | N=520 --> 310 Trial primary completion date: Mar 2019 --> Sep 2020
  • ||||||||||  clarithromycin / Generic mfg.
    Clinical, Journal:  Recurrent bilateral breast abscess due to Mycobacterium abscessus in an immune-competent woman. (Pubmed Central) -  Nov 3, 2020   
    Amikacin was replaced with oral levofloxacin due to bilateral sensory-neural hearing loss for higher frequencies after 6 months. Suspicion and identification of NTM are important as the treatment involves long-term combination antibacterial therapy along with surgical debridement for extensive infection or when implants are involved.